1 completed, 1 suspended, 1 unknown. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Suspended 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Stuttering: new trials by email Literature Review of Stuttering trials Research Report on Stuttering
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Ecopipam 50mg, Ecopipam 100mg - Stuttering, Adult, Childhood-onset Fluency Disorder | Phase 2 / Phase 3 | Unknown | Gerald Maguire, MD | 10 | 2016-09-01 | 2016-10-26 |
| A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering Asenapine - Stuttering | Phase 3 | Suspended | University of California, Irvine | 32 | 2012-09-01 | 2014-05-20 |
| A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering pagoclone, placebo - Stuttering | Phase 2 / Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 321 | 2009-02-01 | 2012-08-28 |
Childhood-Onset Fluency Disorder (1) · Communication Disorders (1) · Language Disorders (1) · Speech Disorders (1)
Nervous System Diseases (3) · Neurobehavioral Manifestations (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Communication Disorders (2) · Language Disorders (2) · Speech Disorders (2) · Mental Disorders (1) · Neurodevelopmental Disorders (1)
asenapine (1) · ecopipam (1) · pagoclone (1)
Endo USA Inc., a Keenova Therapeutics Company (1) · Gerald Maguire, MD (1) · University of California, Irvine (1)
United States (3)
PMID 10917410, PMID 12849360, PMID 15026214, PMID 15212606, PMID 15328899, PMID 20075648, PMID 24434529